Related Experiment Video
Updated: Sep 21, 2025
An Optic Nerve Crush Injury Murine Model to Study Retinal Ganglion Cell Survival
Published on: April 25, 2011
Inhibiting multiple forms of cell death optimizes ganglion cells survival after retinal ischemia reperfusion injury
Qiyu Qin1,2, Naiji Yu1,2, Yuxiang Gu1,2
1Eye Center, the Second Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, Zhejiang Province, China.
Abstract:
Progressive retinal ganglion cells (RGCs) death that triggered by retinal ischemia reperfusion (IR), leads to irreversible visual impairment and blindness, but our knowledge of post-IR neuronal death and related mechanisms is limited. In this study, we first demonstrated that apart from necroptosis, which occurs before apoptosis, ferroptosis, which is characterized by iron deposition and lipid peroxidation, is involved in the whole course of retinal IR in mice. Correspondingly, all three types of RGCs death were found in retina samples from human glaucoma donors. Further, inhibitors of apoptosis, necroptosis, and ferroptosis (z-VAD-FMK, Necrostatin-1, and Ferrostatin-1, respectively) all exhibited marked RGC protection against IR both in mice and primary cultured RGCs, with Ferrostatin-1 conferring the best therapeutic effect, suggesting ferroptosis plays a more prominent role in the process of RGC death. We also found that activated microglia, Müller cells, immune responses, and intracellular reactive oxygen species accumulation following IR were significantly mitigated after each inhibitor treatment, albeit to varying degrees. Moreover, Ferrostatin-1 in combination with z-VAD-FMK and Necrostatin-1 prevented IR-induced RGC death better than any inhibitor alone. These findings stand to advance our knowledge of the post-IR RGC death cascade and guide future therapy for RGC protection.
Insights
Retinal ganglion cell (RGC) death after ischemia reperfusion (IR) involves apoptosis, necroptosis, and ferroptosis. Ferroptosis inhibition offered the best RGC protection, highlighting its key role in vision loss.
Area of Science:
- Neuroscience
- Ophthalmology
- Cell Biology
Background:
- Progressive retinal ganglion cell (RGC) death following retinal ischemia reperfusion (IR) causes irreversible vision loss.
- Mechanisms of post-IR RGC death are not fully understood, limiting therapeutic strategies.
Purpose of the Study:
- To investigate the roles of apoptosis, necroptosis, and ferroptosis in RGC death after IR.
- To evaluate the therapeutic potential of inhibiting these cell death pathways for RGC protection.
Main Methods:
- Induction of retinal IR in a mouse model.
- Analysis of RGC death pathways (apoptosis, necroptosis, ferroptosis) in mouse retinas and human glaucoma donor samples.
- Treatment with specific inhibitors: z-VAD-FMK (apoptosis), Necrostatin-1 (necroptosis), and Ferrostatin-1 (ferroptosis).
- Assessment of RGC survival and related cellular responses (microglia activation, oxidative stress).
Main Results:
- Ferroptosis, alongside apoptosis and necroptosis, contributes to RGC death during retinal IR.
- Inhibitors of all three pathways demonstrated RGC protection in vivo and in vitro.
- Ferrostatin-1 (ferroptosis inhibitor) provided the most significant RGC protection.
- Inhibitor treatments reduced microglial activation, immune responses, and reactive oxygen species accumulation.
- Combination therapy (Ferrostatin-1 with z-VAD-FMK and Necrostatin-1) enhanced RGC protection.
Conclusions:
- Ferroptosis is a critical pathway in RGC death following retinal IR.
- Targeting ferroptosis, potentially in combination with other cell death pathways, offers a promising therapeutic strategy for preventing vision loss due to IR.
- Findings advance understanding of the RGC death cascade and inform future treatments for RGC protection.
